使用Pirfenidone向转化生长因子β (TGF-β),这是结直肠癌中潜在的重定位治疗策略
Hamid Jamialahmadi1,2,3, Seyedeh Elnaz Nazari1, Hamid TanzadehPanah1,2,4
1Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
皮尔芬尼 (PFD),是一种转化生长因子β (TGF-β) 抑制剂,抑制了结直肠癌 (CRC) 细胞的增殖和迁移. 与5-甲 (5-FU) 结合的PFD显示了增强CRC治疗的潜力.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 瘤微环境,包括转化生长因子β (TGF-β),可以限制结肠直肠癌 (CRC) 治疗疗效.
- TGF-β信号传递在CRC进展,扩散和转移中发挥着关键作用.
研究的目的:
- 在临床前结直肠癌模型中研究TGF-β抑制剂Pirfenidone (PFD) 的治疗潜力.
- 为了评估单独的PFD和与5-fluorouracil (5-FU) 结合的CRC中的抗瘤活性.
主要方法:
- 使用MTT和伤口愈合试验对PFD的抗增殖和抗迁移效应进行体外评估.
- 在CRC异种移植模型中对PFD抗瘤活性,组织病理学和副作用的体内评估.
- 对分子标记物的分析,包括生存素,MMP9,E-cadherin和原.
主要成果:
- PFD显著抑制了CRC细胞的增殖和迁移,调节了幸存者和MMP9/E-cadherin.
- 通过影响原蛋白和E-cadherin,PFD抑制了TGF-β诱导的瘤进展,纤维化和炎症.
- 与单独治疗相比,PFD和5-FU的组合显示出增强的抗瘤作用.
结论:
- 用PFD准TGF-β通路显示出减少CRC细胞增殖和迁移的希望.
- PFD,特别是与5-FU结合,可能提供一种新的治疗策略,以改善CRC治疗结果.
- 通过PFD抑制TGF-β信号传递可以减轻瘤进展和CRC相关的 stromal变化.
更多相关视频
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
TGF - β Signaling Pathway
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules
